Bellus Health: BELLUS Health- developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. BELLUS' lead product candidate, BLU-5937, is being developed for the treatment of chronic cough (Phase II announced July 2020) and chronic pruritus (Phase II planned to begin 1H20).

BELLUS' Phase II for chronic cough, the RELIEF study is a dose-escalation, placebo-controlled, and crossover design to assess the efficacy, safety, and tolerability of BLU-5937, a highly selective P2X3 antagonist, at four doses; 25, 50, 100 and 200 mg, administered orally, twice-daily (BID). Approximately 65 patients with refractory chronic cough are expected to be enrolled at twelve clinical sites in the United Kingdom and United States.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
North America
Clinical Stage
Phase l or ll
Disease Space
Respiratory
Industry
Biotechnology
Listing
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Small Molecule
Website:
Profiles:
Address:
275 Armand-Frappier Boulevard
Laval, Quebec H7V 4A7
Canada

Company Participants at Solebury Trout Management Access SF 2020

  • Catherine Bonucelli
  • Roberto Bellini, President & CEO
  • Tony Matzouranis

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of BELLUS Health Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
RTW Investments LP 12.49 5,490,992 54.69 13F 2020-03-31
OrbiMed Advisors LLC 11.68 5,137,216 51.17 Stakes 2020-06-10
Fidelity Management & Research Co. LLC 9.35 4,111,149 40.95 13F 2020-03-31
Polar Capital LLP 5.30 2,330,893 23.22 13F 2020-03-31
Boxer Capital LLC 4.04 1,775,000 17.68 13F 2020-03-31
AWM Investment Co., Inc. 3.64 1,600,000 15.94 13F 2020-03-31
Consonance Capital Management LP 3.63 1,597,503 15.91 13F 2020-03-31
First Manhattan Co. 2.91 1,279,287 12.74 13F 2020-03-31
Acuta Capital Partners LLC 2.43 1,070,000 10.66 13F 2020-03-31
Logos Global Management LP 1.76 775,377 7.72 13F 2020-03-31
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.